Global Endocrine Therapy Drugs (ETDs) Market, by Drug Type (Anti-diabetic Drugs, Anti-osteoporosis Drugs, Contraceptive Drugs, Breast Cancer Drugs, and Others {Menopause Drugs, among others}), by Application (Diabetes, Breast Cancer, Osteoporosis, Menopause, Contraception, and Others {Gender Reassignment Surgery, Hypothyroidism, among others}), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 28,958.4 million in 2022 and is expected to exhibit a CAGR of 5.1% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the global endocrine therapy drugs (ETDs) market growth over the forecast period.
For instance, in July 2018, Novartis AG, a Switzerland based pharmaceutical company received the U.S. Food and Drugs Administration (FDA) approval for its endocrine therapy drug Kisqali (ribociclib), which is to be used in combination with an aromatase inhibitor for the treatment of pre/post-menopausal women with breast cancer.
Global Endocrine Therapy Drugs (ETDs) Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 392 million cases and 4.7 million deaths due to Coronavirus (COVID-19) were reported up till February 6, 2022, across the globe.
The COVID-19 pandemic has affected several markets across the globe, however, it is expected to positively impact the global endocrine therapy drugs (ETDs) market, owing to intensive research being carried out to determine the role of hormones and endocrine therapy drugs in prevention of COVID-19. For instance, according to a research article published by the Cancers journal, an open access journal of oncology, published by MDPI in August 2020, high testosterone levels might regulate transmembrane serine protease 2 (TMPRSS2), a cell receptor protein involved in the entry of coronavirus. Thus, clinical studies on antiandrogens (a type of endocrine therapy drug) such as bicalutamide and enzalutamide are ongoing to determine the role of antiandrogens in providing immunity against severe COVID-19 infection in cancer patients.
Browse 32 Market Data Tables and 27 Figures spread through 163 Pages and in-depth TOC on “Endocrine Therapy Drugs (ETDs) Market”- Global Forecast to 2030, by Drug Type (Anti-diabetic Drugs, Anti-osteoporosis Drugs, Contraceptive Drugs, Breast Cancer Drugs, and Others {Menopause Drugs, among others}), by Application (Diabetes, Breast Cancer, Osteoporosis, Menopause, Contraception, and Others {Gender Reassignment Surgery, Hypothyroidism, among others}), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the global endocrine therapy drugs (ETDs) market, click the link below:
https://www.coherentmarketinsights.com/market-insight/endocrine-therapy-drugs-market-5193
Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations and acquisitions, in order to strengthen their position in the market. For instance, in April 2021, Myovant Sciences GmbH, a U.K. based bio-pharmaceutical company and Pfizer Inc., a U.S. based pharmaceutical company announced a collaboration for development and commercialization of ORGOVYX (Relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist to be used as an endocrine therapy for the treatment of advanced prostate cancer in men, and uterine fibroids and endometriosis in women.
Key Takeaways of the Global Endocrine Therapy Drugs (ETDs) Market:
- The global endocrine therapy drugs (ETDs) market is expected to exhibit a CAGR of 5.1% over the forecast period, owing to rising regulatory approvals of endocrine therapy drugs. For instance, in August 2017, AstraZeneca, a U.K. based pharmaceutical company received the U.S. Food and Drugs Administration (FDA) approval for its endocrine therapy drug Faslodex (fulvestrant) as a mono-therapy for post-menopausal women with breast cancer.
- Among application, breast cancer segment is expected to account for the largest market share in 2022, owing to rising incidence and prevalence of breast cancer. For instance, according to the American Cancer Society Facts and Figures 2022, it is estimated that in 2022, the number of new cases of breast cancer reported in women and men in the U.S. would be around 287,850 and 2,710, respectively.
- Key players operating in the global endocrine therapy drugs (ETDs) market include Novo Nordisk A/S, AstraZeneca, Generex Biotechnology, Orion Pharma AB, Sanofi, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co.,Inc., Bayer AG, Eli Lilly and Company, Abbott, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., TherapeuticsMD, Inc., Pfizer Inc., Allergan, BioSante Pharmaceuticals, Amgen Inc., Noven Pharmaceuticals, Inc., and QuatRx Pharmaceuticals
